Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Medicina de Família e Comunidade (Online) |
Texto Completo: | https://www.rbmfc.org.br/rbmfc/article/view/2573 |
Resumo: | Quaternary prevention: action taken to recognize people or populations at risk of overmedicalization and to protect them, suggesting scientifically and ethically acceptable procedures. In 2019, a disease classified as Coronavirus-Induced-Disease, responsible for the COVID-19 pandemic, emerged in Wuhan. Lives are being cut short and the search for treatment is a global public health issue. In vitro, hydroxychloroquine and chloroquine inhibit this agent, so it was suggested that such drugs should be part of the early treatment. A review was performed in PubMed and LILACS databases and manual search of journals in The New England Journal of Medicine (NEJM) and in the Journal of the American Medical Association (JAMA), under the terms: “hydroxychloroquine, chloroquine and COVID-19”,“Hydroxychloroquine, chloroquine and COVID-19” and “chloroquine and COVID-19”. The Exclusion Criteria: duplicate articles, hydroxychloroquine and chloroquine outside the context of COVID-19, other aspects of COVID-19 and magazines sponsored by the pharmaceutical industry. 115 articles were found in the databases after applying the exclusion criteria and 6 were selected for review. Other studies on quaternary prevention were researched in order to discuss the excess of medical intervention. There is still no ideal treatment to control the virus. It is up to the health professionals, in particular, the Family Practice Doctors, the critical thinking applied to all the results presented in the studies, no matter how attractive they may seem at first sight. |
id |
SBMFC-1_9a7fa93386a726a7f1586a448cc604d8 |
---|---|
oai_identifier_str |
oai:ojs.rbmfc.org.br:article/2573 |
network_acronym_str |
SBMFC-1 |
network_name_str |
Revista Brasileira de Medicina de Família e Comunidade (Online) |
repository_id_str |
|
spelling |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk?Prevención cuaternaria y la prescripción de Cloroquina y Hidroxicloroquina en la COVID-19: ¿Vale la pena pecar por el exceso?Prevenção Quaternária e a Prescrição de Cloroquina e Hidroxicloroquina na COVID-19: vale a pena pecar pelo excesso?Quaternary PreventionHydroxychloroquineChloroquineCoronavirus Infections.Prevención CuaternariaHidroxicloroquinaCloroquinaInfecciones por Coronavirus.Prevenção QuaternáriaHidroxicloroquinaCloroquinaInfecções por Coronavirus.Quaternary prevention: action taken to recognize people or populations at risk of overmedicalization and to protect them, suggesting scientifically and ethically acceptable procedures. In 2019, a disease classified as Coronavirus-Induced-Disease, responsible for the COVID-19 pandemic, emerged in Wuhan. Lives are being cut short and the search for treatment is a global public health issue. In vitro, hydroxychloroquine and chloroquine inhibit this agent, so it was suggested that such drugs should be part of the early treatment. A review was performed in PubMed and LILACS databases and manual search of journals in The New England Journal of Medicine (NEJM) and in the Journal of the American Medical Association (JAMA), under the terms: “hydroxychloroquine, chloroquine and COVID-19”,“Hydroxychloroquine, chloroquine and COVID-19” and “chloroquine and COVID-19”. The Exclusion Criteria: duplicate articles, hydroxychloroquine and chloroquine outside the context of COVID-19, other aspects of COVID-19 and magazines sponsored by the pharmaceutical industry. 115 articles were found in the databases after applying the exclusion criteria and 6 were selected for review. Other studies on quaternary prevention were researched in order to discuss the excess of medical intervention. There is still no ideal treatment to control the virus. It is up to the health professionals, in particular, the Family Practice Doctors, the critical thinking applied to all the results presented in the studies, no matter how attractive they may seem at first sight.Prevención cuaternaria: acción realizada para reconocer a las personas o poblaciones en riesgo de sobremedicalización y protegerlas, sugiriendo procedimientos científica y éticamente aceptables. En 2019, surgió en Wuhan una enfermedad clasificada como enfermedad inducida por coronavirus, responsable de la pandemia de COVID-19. Se están acortando vidas y la búsqueda de tratamiento es un problema de salud pública mundial. In vitro, la hidroxicloroquina y la cloroquina inhiben este agente y se sugirió que tales fármacos deberían formar parte del tratamiento temprano. Se realizó una revisión en las bases de datos PubMed y LILACS y búsqueda manual de revistas en The New England Journal of Medicine (NEJM) y en el Journal of the American Medical Association (JAMA), bajo los términos: “hydroxychloroquine, cloroquina y COVID-19” , “Hidroxicloroquina, cloroquina y COVID-19” y “Cloroquina y COVID-19”. Los Criterios de Exclusión: artículos duplicados, hidroxicloroquina y cloroquina fuera del contexto de COVID-19, otros aspectos de COVID-19 y periódicos patrocinados por la industria farmacéutica. Se encontraron 115 artículos en las bases de datos luego de aplicar los criterios de exclusión y se seleccionaron 6 para revisión. Se investigaron otros estudios sobre prevención cuaternaria para discutir el exceso de intervención médica. Todavía no existe un tratamiento ideal para controlar el virus. Depende de los profesionales de la salud, en particular, los Médicos de Familia y Comunitarios, el pensamiento crítico aplicado a todos los resultados presentados en los estudios, por muy atractivos que parezcan en un principio.Prevenção quaternária: ação feita para reconhecer pessoas ou populações em risco de supermedicalização e protegê-las, sugerindo procedimentos científica e eticamente aceitáveis. Em 2019, emergiu em Wuhan, uma doença classificada como Coronavirus-Induced-Disease, responsável pela pandemia por COVID-19. Vidas estão sendo ceifadas e a busca por tratamento é uma questão de saúde pública planetária. In vitro, a hidroxicloroquina e a cloroquina inibem esse agente, sendo sugerido que tais medicamentos fizessem parte do tratamento precoce. Realizou-se uma revisão em bancos de dados PubMed e LILACS e busca manual de periódicos no The New England Journal of Medicine (NEJM) e no Journal of the American Medical Association (JAMA), pelos termos: “hidroxicloroquina, cloroquina e COVID-19”, “hydroxychloroquine, chloroquine and COVID-19” e “cloroquina e COVID-19”. Critérios de exclusão: artigos duplicados, hidroxicloroquina e cloroquina fora do contexto da COVID-19, outros aspectos da COVID-19 e revistas patrocinadas pela indústria farmacêutica. Foram encontrados 115 artigos nos bancos de dados, após a aplicação dos critérios de exclusão e 6 foram selecionados para a revisão. Pesquisou-se outros estudos sobre prevenção quaternária, a fim de discutir o excesso de intervenção médica. Ainda não existe um tratamento ideal para controlar o vírus. Cabe aos profissionais de saúde, em especial, os Médicos de Família e Comunidade, o pensamento crítico aplicado a todos os resultados apresentados nos estudos, por mais atrativos que estes pareçam à primeira vista.Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)2021-07-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos Originais; Original Articlesapplication/pdfhttps://www.rbmfc.org.br/rbmfc/article/view/257310.5712/rbmfc16(43)2573Revista Brasileira de Medicina de Família e Comunidade; Vol. 16 No. 43 (2021); 2573Revista Brasileira de Medicina de Família e Comunidade; Vol. 16 Núm. 43 (2021); 2573Revista Brasileira de Medicina de Família e Comunidade; v. 16 n. 43 (2021); 25732179-79941809-5909reponame:Revista Brasileira de Medicina de Família e Comunidade (Online)instname:Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)instacron:SBMFCporhttps://www.rbmfc.org.br/rbmfc/article/view/2573/1615Copyright (c) 2021 Alexandre José de Melo Neto, Denise Mota Araripe Pereira Fernandes, Lana Muriely Borges de Assis, Marina de Lima Pinheiro, Anne Thaísa Dantas Carvalho, Melissa Maria Medeiros de Moraishttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMelo Neto, Alexandre José deFernandes, Denise Mota Araripe PereiraAssis, Lana Muriely Borges dePinheiro, Marina de LimaCarvalho, Anne Thaísa DantasMorais, Melissa Maria Medeiros de2021-12-30T00:21:54Zoai:ojs.rbmfc.org.br:article/2573Revistahttp://www.rbmfc.org.br/index.php/rbmfchttps://www.rbmfc.org.br/rbmfc/oai||david@sbmfc.org.br2179-79941809-5909opendoar:2021-12-30T00:21:54Revista Brasileira de Medicina de Família e Comunidade (Online) - Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)false |
dc.title.none.fl_str_mv |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? Prevención cuaternaria y la prescripción de Cloroquina y Hidroxicloroquina en la COVID-19: ¿Vale la pena pecar por el exceso? Prevenção Quaternária e a Prescrição de Cloroquina e Hidroxicloroquina na COVID-19: vale a pena pecar pelo excesso? |
title |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? |
spellingShingle |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? Melo Neto, Alexandre José de Quaternary Prevention Hydroxychloroquine Chloroquine Coronavirus Infections. Prevención Cuaternaria Hidroxicloroquina Cloroquina Infecciones por Coronavirus. Prevenção Quaternária Hidroxicloroquina Cloroquina Infecções por Coronavirus. |
title_short |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? |
title_full |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? |
title_fullStr |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? |
title_full_unstemmed |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? |
title_sort |
Quaternary prevention and the prescription of Chloroquine and Hydroxychloroquine in COVID-19: are they worth the risk? |
author |
Melo Neto, Alexandre José de |
author_facet |
Melo Neto, Alexandre José de Fernandes, Denise Mota Araripe Pereira Assis, Lana Muriely Borges de Pinheiro, Marina de Lima Carvalho, Anne Thaísa Dantas Morais, Melissa Maria Medeiros de |
author_role |
author |
author2 |
Fernandes, Denise Mota Araripe Pereira Assis, Lana Muriely Borges de Pinheiro, Marina de Lima Carvalho, Anne Thaísa Dantas Morais, Melissa Maria Medeiros de |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Melo Neto, Alexandre José de Fernandes, Denise Mota Araripe Pereira Assis, Lana Muriely Borges de Pinheiro, Marina de Lima Carvalho, Anne Thaísa Dantas Morais, Melissa Maria Medeiros de |
dc.subject.por.fl_str_mv |
Quaternary Prevention Hydroxychloroquine Chloroquine Coronavirus Infections. Prevención Cuaternaria Hidroxicloroquina Cloroquina Infecciones por Coronavirus. Prevenção Quaternária Hidroxicloroquina Cloroquina Infecções por Coronavirus. |
topic |
Quaternary Prevention Hydroxychloroquine Chloroquine Coronavirus Infections. Prevención Cuaternaria Hidroxicloroquina Cloroquina Infecciones por Coronavirus. Prevenção Quaternária Hidroxicloroquina Cloroquina Infecções por Coronavirus. |
description |
Quaternary prevention: action taken to recognize people or populations at risk of overmedicalization and to protect them, suggesting scientifically and ethically acceptable procedures. In 2019, a disease classified as Coronavirus-Induced-Disease, responsible for the COVID-19 pandemic, emerged in Wuhan. Lives are being cut short and the search for treatment is a global public health issue. In vitro, hydroxychloroquine and chloroquine inhibit this agent, so it was suggested that such drugs should be part of the early treatment. A review was performed in PubMed and LILACS databases and manual search of journals in The New England Journal of Medicine (NEJM) and in the Journal of the American Medical Association (JAMA), under the terms: “hydroxychloroquine, chloroquine and COVID-19”,“Hydroxychloroquine, chloroquine and COVID-19” and “chloroquine and COVID-19”. The Exclusion Criteria: duplicate articles, hydroxychloroquine and chloroquine outside the context of COVID-19, other aspects of COVID-19 and magazines sponsored by the pharmaceutical industry. 115 articles were found in the databases after applying the exclusion criteria and 6 were selected for review. Other studies on quaternary prevention were researched in order to discuss the excess of medical intervention. There is still no ideal treatment to control the virus. It is up to the health professionals, in particular, the Family Practice Doctors, the critical thinking applied to all the results presented in the studies, no matter how attractive they may seem at first sight. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-14 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos Originais; Original Articles |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.rbmfc.org.br/rbmfc/article/view/2573 10.5712/rbmfc16(43)2573 |
url |
https://www.rbmfc.org.br/rbmfc/article/view/2573 |
identifier_str_mv |
10.5712/rbmfc16(43)2573 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.rbmfc.org.br/rbmfc/article/view/2573/1615 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
publisher.none.fl_str_mv |
Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
dc.source.none.fl_str_mv |
Revista Brasileira de Medicina de Família e Comunidade; Vol. 16 No. 43 (2021); 2573 Revista Brasileira de Medicina de Família e Comunidade; Vol. 16 Núm. 43 (2021); 2573 Revista Brasileira de Medicina de Família e Comunidade; v. 16 n. 43 (2021); 2573 2179-7994 1809-5909 reponame:Revista Brasileira de Medicina de Família e Comunidade (Online) instname:Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) instacron:SBMFC |
instname_str |
Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
instacron_str |
SBMFC |
institution |
SBMFC |
reponame_str |
Revista Brasileira de Medicina de Família e Comunidade (Online) |
collection |
Revista Brasileira de Medicina de Família e Comunidade (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Medicina de Família e Comunidade (Online) - Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC) |
repository.mail.fl_str_mv |
||david@sbmfc.org.br |
_version_ |
1752122109728915456 |